Company intelligence / Profile preview

Aevitas Therapeutics

New York, New York, United States

Ownership: Public · FBIO
Development stage: Other

Overview

The company's lead program was development of an AAV-based gene therapy delivering a shortened and optimized form of complement factor H (sCFH). Preclinical results demonstrated robust expression and functional restoration of complement regulation in vitro and in animal models. The technology was sold to 4D Molecular Therapeutics for further development as 4D-175 for geographic atrophy.

Therapeutic areas: HematologyOphthalmologyImmunology
Modalities: Gene therapyBiologic
Industry: Biotech

Partnerships

University of Pennsylvania (research and technology development)University of Massachusetts Medical School (construct optimization, advisory board)4D Molecular Therapeutics (asset sale, development of sCFH as 4D-175)

Beyond the preview

Go deeper on Aevitas Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aevitas Therapeutics.

Explore the full profile